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Abstract: Cowpox virus (CPXV) is a zoonotic virus and endemic in wild rodent populations in
Eurasia. Serological surveys in Europe have reported high prevalence in different vole and mouse
species. Here, we report on experimental CPXV infections of bank voles (Myodes glareolus) from
different evolutionary lineages with a spectrum of CPXV strains. All bank voles, independently
of lineage, sex and age, were resistant to clinical signs following CPXV inoculation, and no virus
shedding was detected in nasal or buccal swabs. In-contact control animals became only rarely
infected. However, depending on the CPXV strain used, inoculated animals seroconverted and viral
DNA could be detected preferentially in the upper respiratory tract. The highest antibody titers
and virus DNA loads in the lungs were detected after inoculation with two strains from Britain and
Finland. We conclude from our experiments that the role of bank voles as an efficient and exclusive
CPXV reservoir seems questionable, and that CPXV may be maintained in most regions by other
hosts, including other vole species. Further investigations are needed to identify factors that allow
and modulate CPXV maintenance in bank voles and other potential reservoirs, which may also
influence spill-over infections to accidental hosts.
Keywords: Cowpox virus; reservoir; host; voles
1. Introduction
Over the past 15 years, many new viruses and known viruses have (re-)emerged and are frequently
causing zoonotic diseases [1,2]. The viruses are either transmitted to humans from non-human
vertebrates (vertebrate-borne diseases) or by arthropods (vector-borne diseases). Cowpox virus (CPXV)
is a zoonotic pathogen known to circulate among rodents in Europe [1]. Human CPXV infections are
relatively rare [3–9] and CPXV usually causes a self-limiting disease in humans, predominantly lesions
on hands or face [3–9]. However, in immunocompromised patients, CPXV infections can readily
generalize and result in severe and sometimes lethal infections [4,5].
The species Cowpox virus belongs to the genus Orthopoxvirus (OPV), subfamily Chordopoxvirinae,
family Poxviridae. CPXV is endemic in Europe and Northern and Central Asia [10,11]. Many mammal
species are known to be susceptible to CPXV infection, among them cats [6,12], rats [7–9], alpacas [13],
elephants [14], and primates such as cotton-top tamarins [15]. Cats seem to be the main source of
Viruses 2017, 9, 391; doi:10.3390/v9120391 www.mdpi.com/journal/viruses
Viruses 2017, 9, 391 2 of 12
human CPXV infections, although wild rodents, primarily voles, are believed to be the definitive
reservoir hosts for the virus [10,11].
Investigations on wild rodents as potential reservoir hosts of CPXV started in England in the 1980s.
Until now, serological surveys indicating CPXV infections in wild rodents have been reported for
several countries of Eurasia: The United Kingdom [16–18], Belgium [19], Finland [20,21], Norway [22],
Germany [21,23], Turkmenia [24], Vietnam [25], Georgia [26] and Hungary [27]. Here, voles (bank vole,
Myodes glareolus [18,19,21,27], field vole, Microtus agrestis [17,21]), and murine rodents such as the
striped field mouse, Apodemus agrarius [21], wood mouse, Apodemus sylvaticus [19,22], and Norway rat
(Rattus norvegicus [22]), tested positive for CPXV-specific antibodies. Bank voles were shown to reach
maximum seroprevalence of 71% in Hungary [27], 64% in Belgium [19], and 72% in the UK [18].
In the UK, different field studies indicated the circulation of CPXV in rodents and demonstrated
peaks of infections in bank voles and wood mice, although interspecies transmission was negligible [28].
Correlations of CPXV infection and vole survival [29] or interactions of CPXV and other microparasites
in simultaneously infected voles were observed [30]. First experimental infections in the late 1990s
revealed that young bank voles (three to five weeks old) developed antibodies between 10 and
14 days post infection (dpi) independently of the inoculation route (CPXV strain L97; intradermal,
subcutaneous or oronasal) [31]. In addition, Feore et al. reported that CPXV infections of bank voles
reduced fecundity by increasing the time to first litter [32].
However, CPXV has not yet been isolated from vole or mice species other than the common
vole (Microtus arvalis) [33]. As isolation is one of the criteria supporting the identification of a species
being a natural reservoir of a certain pathogen (according to [34]), the role of bank voles in central
Europe for CPXV epidemiology is doubtful. Post-glacial colonization of Europe by bank voles from
different refuges resulted in the establishment of different evolutionary lineages, with the Western,
Eastern and Carpathian lineages in Central Europe [35,36]. The experimental inoculation of the
supposed reservoir species resulting in infection and shedding is a criterion that needs to be met
for a natural reservoir definition [34]. Our recent infection experiments showed susceptibility of
common voles to oronasal CPXV infection, which also resulted in respiratory symptoms and virus
excretion [33]. We, therefore, decided to perform similar experimental inoculations with bank voles
of different evolutionary lineages and age groups to further determine their potential as putative
CPXV reservoir species. The CPXV isolates used here originated from different geographical origin,
from accidental hosts (human, rat or cat), and also from one reservoir host species, the common vole.
With the polyphyletic nature of the species Cowpox virus in mind, members of four CPXV clades
(according to [37]) were used. In addition, CPXV was applied by different inoculation routes.
2. Materials and Methods
2.1. Viruses
CPXV strains of different origins (summarized in Table 1) were propagated on Vero76 cells (Collection
of Cell Lines in Veterinary Medicine (CCLV), Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany).
2.2. Animals
Outbred bank voles (Myodes glareolus) originated from in house-breeding and were kept under
standardized conditions: type III cages; 22 ◦C; 12/12 h light cycle, ≈60% humidity; water and rodent
pellets ad libitum as the diet. The specific pathogen-free status with regard to CPXV of the breeding
colonies was controlled on a regular basis by serological assays. The breeding colonies originated
from voles of the Western evolutionary lineage, provided by the Federal Environmental Agency in
Berlin, Germany, and voles of the Carpathian evolutionary lineage, provided by Jagiellonian University
Krakow, Poland. PCR amplification and sequencing of the partial cytochrome b gene following a
standard protocol [42] confirmed the different evolutionary lineages (data not shown).
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Table 1. Characterization of CPXV strains used for experimental infections.
Isolate (Accession Number) Host Origin Genetic Clade [37] Reference
Brighton Red (AF482758) Human UK, Northern Europe CPXV-like 2 [38]
RatPox09 (LN864565) Pet rat Germany, Central Europe VARV-like [39]
Ger 91/3 (DQ437593) Human Germany, Central Europe CPXV-like 2 [40]
Ger/2007/Vole (LT896722) Common vole Germany, Central Europe CPXV-like 2 [37]
FM2292 (LN864566) Common vole Germany, Central Europe CPXV-like 2 [33]
Ger/2010/Cat (LT896729) Cat Germany, Central Europe CPXV-like 1 [37]
FIN_MAN_2000 (HQ420893) Human Finland, Northern Europe VACV-like [41]
CPXV, cowpox virus; VACV, vaccinia virus, VARV, variola virus.
2.3. Infection Experiments and Sampling
The animal experiments were evaluated by the responsible ethics committee of the State
Office for Agriculture, Food Safety and Fishery in Mecklenburg-Western Pomerania (LALFF M-V)
and governmental approval was obtained (registration number 7221.3-1.1-020/13, 27 May 2013).
The design of all experiments is summarized in Table 2. Initially, we inoculated bank voles of the
Western lineage with seven CPXV strains originating from different host species (Tables 1 and 2,
experiment #1). The voles were of mixed ages (3 to 4 months or 1-year-old) and mixed sex. Virus was
given intranasally at 105 TCID50/animal. Body temperature, weight, and general health status were
checked daily over a period of 21 days. In addition, nasal swabs were taken every other day until 21 dpi
by applying a wetted swab onto the rhinarium of the individual vole. Some animals were euthanized
for autopsy on 5 dpi or 21 dpi, when different organ samples (rhinarium and nasal epithelia, skin, liver,
lung, spleen, trachea) and blood were collected individually.
Further experiments were done to examine the influence of the application route, the age
and origin of the voles (Table 2, experiments #2–#5). As indicated, in-contact animals were
grouped together with CPXV-inoculated animals in some experiments. After 24 h of separation,
contact voles were caged together with CPXV-inoculated animals to determine transmission
potential. All nasal swabs were directly suspended in 2 mL cell culture medium (mixture of
equal volumes of Eagle MEM (Hanks’ balanced salts solution) and Eagle MEM (Earle’s balanced
salts solution), 2 mM L-Glutamine, nonessential amino acids, adjusted to 850 mg/L NaHCO3,
120 mg/L sodium pyruvate, 10% fetal bovine serum (FBS), pH 7.2; suited for closed tissue
culture vessels and incubation under 2.5% CO2 atmosphere and supplemented with antibiotics:
1% enroflaxin (Bayer, Leverkusen, Germany), 0.5% lincomycin (WDT, Garbsen, Germany) and 0.2%
amphotericin/gentamicin (Gibco Life technologies, Carlsbad, Germany). The organ samples were
placed into reaction tubes of 1 mL cell culture medium (see above) supplemented with 1%
penicillin-streptomycin and a stainless-steel bead (5 mm diameter).
2.4. Analysis of the Samples
Viral DNA loads of all samples were determined by quantitative PCR (qPCR) using OPV-specific
primers [43]. Organ tissues were homogenized (TissueLyser II; Qiagen; Hilden, Germany).
DNA extraction was done semi-automatically by the BioSprint 96 instrument (Qiagen) using the
NucleoMag VET kit (Macherey-Nagel, Düren, Germany). The sera were analyzed by an indirect
immunofluorescence (IF) assay to detect OPV-specific antibodies. In brief, serum samples were first
inactivated for 30 min at 56 ◦C. Subsequently, CPXV-infected Hep2 cells (fixed with methanol-acetone
at 1:1 and incubated with Tris-buffered saline plus Tween (TBS-T) for 30 min) were incubated for
1 h at room temperature with different serum dilutions (1:20, 1:40, 1:80, 1:160, 1:320). After three
washing steps with PBS, a commercial anti-mouse secondary antibody conjugated to Alexa488
(Thermo Fisher Scientific, Waltham, MA, USA) was applied. The cells were visualized under a
fluorescence microscope. The titer was taken as reciprocal of the greatest serum dilution, which
showed positive detection and those animals with reaction at titers of ≥1:40 were considered positive.
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Table 2. Design of the animal experiments.
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2.5. Statistics
Results were statistically evaluated per groups by ANOVA using SPSS (IBM, Ehningen, Germany).
The Tukey HSD test (p = 0.05) was performed (SPSS) to determine whether results were significantly
different between groups.
3. Results
3.1. CPXV Infection of Bank Voles of the Western Evolutionary Lineage with Different CPXV Strains Induced
no Clinical Signs (Experiment #1)
The initial infection experiment (Table 2, experiment #1) did not result in clinical signs when any
of the Western lineage bank voles were inoculated intranasally with different CPXV strains. In addition,
body weight and body temperature were stable for all animals for the duration of the observation
period (data not shown). Most animals developed antibodies, but with varying titers (Table 3, Table S1).
Inoculation with the reference CPXV strain Brighton Red or the CPXV isolate FIN_MAN_2000 induced
anti-CPXV antibodies in all animals and resulted in the highest antibody titers (up to 1:320, Table S1).
In contrast, in the group inoculated with the common vole-derived CPXV strain Ger/2007/vole,
only one individual developed antibodies with a low titer of 1:20 (Table S1). Statistical evaluation
of antibody titers revealed significant differences of the seropositivity in animals inoculated with
Brighton Red compared to Ger 91/3 and Ger/2007/Vole (Table 3). In addition, antibody titers in
animals inoculated with FIN_MAN_2000 differed significantly from those in voles inoculated with
RatPox09, Ger 91/3 and Ger/2007/Vole (Table 3). The other group comparisons showed no significant
differences (p > 0.05).
The distribution of virus DNA in different organs was tested by qPCR and the results are
summarized in Table 4. On five dpi, viral DNA was detected in the rhinarium and in the trachea
in nearly all animal groups (except the voles inoculated with CPXV RatPox09). In addition, in two
animals inoculated with CPXV Brighton Red or FIN_MAN_2000, respectively, the lungs also scored
positive for viral DNA. Besides the respiratory tract, CPXV DNA could also be found in the skin
(1 x CPXV Brighton Red, 1 x CPXV Ger 91/3). Organ samples from autopsy at 21 dpi were all negative
(data not shown). Furthermore, no viral shedding was detected in the CPXV-inoculated animals over a
period of 21 days (data not shown).
Table 3. Seroconversion rate of CPXV-inoculated bank voles at 21 dpi.
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Table 3. Seroconversion rate of CPXV-inoculated bank voles at 21 dpi. 
CPXV Strain Tukey HSD † Positive Antibody Titers # 
Brighton Red  100% 
FIN_MAN_2000  100% 
RatPox09  40% 
Ger 91/3  67% 
Ger/2007/Vole  0% 
FM2292  60% 
Ger/2010/Cat  67% 
† Post-hoc-test between the serological reactivity at different dilutions (Table S1) of the different 
groups for α < 0.05; #Antibody titers of ≥1:40 were considered positive. 
Table 4. Viral DNA detection in different organs at 5 dpi. 
CPXV Strain 
No. Positive/Total No. of Tested Voles * 
Rhinarium Trachea Liver Spleen Lung Skin 
Brighton Red 4/5 (1) 4/5 (2) 0/5 0/5 4/10 (4) 1/5 (1) 
FIN_MAN_2000 5/5 (1) 3/5 (1) 0/5 0/5 4/10 (0) 0/5 
RatPox09 0/4 0/4 0/4 0/4 08 0/4 
Ger 91/3 1/4 (1) 2/4 (1) 0/4 0/4 0/8 1/4 (0) 
Ger/2007/Vole 1/4 (0) 2/4 (0) 0/4 0/4 0/8 0/4 
FM2292 2/4 (0) 2/4 (1) 0/4 0/4 0/8 0/4 
Ger/2010/Cat 2/4 (0) 2/4 (1) 0/4 0/4 0/8 0/4 
* Cq values of less than 36 were considered positive. Two lung localisations per animal were 
analysed. Numbers in brackets refer to Cq values below 30, which is considered as positive for 
replicating virus. 
3.2. Intranasal Inoculation of Western Lineage Bank Voles with RatPox09 Induced a Stronger Antibody 
Response than Subcutaneous Inoculation (Experiment #2) 
The second experiment (Table 2) was limited to the CPXV strain RatPox09 in order to compare 
the outcome with our previous studies using the same strain in both rats [39] and common voles 
[33]. 
Two different application routes (intranasal, as used in experiment #1, and subcutaneous) were 
tested. Bank voles were checked daily and nasal swabs were taken over a 14-day period. None of the 
inoculated animals showed any clinical signs and all swab samples as well as all organ samples 
scored negative by qPCR. Serum antibodies were detected with the IF test (Table 5), with titers up to 
1:320 (Table S2). Generally, voles inoculated intranasally developed significantly higher antibody 
titers than voles inoculated subcutaneously (p = 0.05; Table 5 and Table S2). One contact animal, 
which was housed together with the intranasally inoculated animals, also produced high titers of 







† t-hoc-test between the serologica rea tivity at differen dilutions (Table S1) of the different groups for α < 0.05;
# Antibody titers of ≥1:40 were considered positive.
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Table 4. Viral DNA detection in different organs at 5 dpi.
CPXV Strain
No. Positive/Total No. of Tested Voles *
Rhinarium Trachea Liver Spleen Lung Skin
Brighton Red 4/5 (1) 4/5 (2) 0/5 0/5 4/10 (4) 1/5 (1)
FIN_MAN_2000 5/5 (1) 3/5 (1) 0/5 0/5 4/10 (0) 0/5
RatPox09 0/4 0/4 0/4 0/4 08 0/4
Ger 91/3 1/4 (1) 2/4 (1) 0/4 0/4 0/8 1/4 (0)
Ger/2007/Vole 1/4 (0) 2/4 (0) 0/4 0/4 0/8 0/4
FM2292 2/4 (0) 2/4 (1) 0/4 0/4 0/8 0/4
Ger/2010/Cat 2/4 (0) 2/4 (1) 0/4 0/4 0/8 0/4
* Cq values of less than 36 were considered positive. Two lung localisations per animal were analysed. Numbers in
brackets refer to Cq values below 30, which is considered as positive for replicating virus.
3.2. Intranasal Inoculation of Western Lineage Bank Voles with RatPox09 Induced a Stronger Antibody
Response than Subcutaneous Inoculation (Experiment #2)
The second experiment (Table 2) was limited to the CPXV strain RatPox09 in order to compare
the outcome with our previous studies using the same strain in both rats [39] and common voles [33].
Two different application routes (intranasal, as used in experiment #1, and subcutaneous) were
tested. Bank voles were checked daily and nasal swabs were taken over a 14-day period. None of
the inoculated animals showed any clinical signs and all swab samples as well as all organ samples
scored negative by qPCR. Serum antibodies were detected with the IF test (Table 5), with titers up to
1:320 (Table S2). Generally, voles inoculated intranasally developed significantly higher antibody titers
than voles inoculated subcutaneously (p = 0.05; Table 5 and Table S2). One contact animal, which was
housed together with the intranasally inoculated animals, also produced high titers of OPV-specific
antibodies (Table S2).
Table 5. Seroconversion rate of CPXV-inoculated bank voles inoculated with CPXV RatPox09 via
different routes, and in contact animals at 14 dpi.
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a le 5. Seroconversion rate of -inoc late  bank voles inoc late  ith  at ox09 via 
different routes, and in contact ani als at 14 dpi. 
CPXV RatPox09 Tukey HSD † Positive Antibody Titers # 
Subcutanous 
Inoculated  50% 
Contact animals  0% 
Intranasal 
Inoculated  83% 
Contact animals  50% 
† Post-hoc-test between serological reactivity at different dilutions (Table S2) groups for p < 0.05;  
# Antibody titers of ≥40 were considered positive. 
3.3. The Evolutionary Bank Vole Lineage Had no Influence on the Results of Intranasal Inoculation with 
RatPox09 (Experiment #3) 
In order to evaluate potential influences of the evolutionary lineage, young voles at an age of 
four weeks from the Western and Carpathian lineage were inoculated intranasally with CPXV 
RatPox09 (Table 2, experiment #3). None of the animals excreted virus over a period of 14 dpi as 
proven by negative swab samples (data not shown). There was also no viral DNA detected in the 
organ samples (data not shown), and the voles produced only low amounts of antibodies with a titer 
of up to 1:80 (Table S3) that did not differ significantly between the two vole lineages. In addition, 
none of the contact animals showed any signs of infection or seroconversion. Interestingly, with the 
restriction that the results were generated in two independent experiments (experiment #2 and 
experiment #3), younger bank voles exhibited significant (ANOVA analysis, p value of 0.00029) 
lower seroconversion rates compared to adult bank voles (greater than four weeks of age). 
3.4. Footpad Inoculation Induced No Clinical Signs, but a Strong Antibody Response, Independent of CPXV 
Strain and Bank Vole Evolutionary Lineage (Experiment #4) 
Next, we investigated the footpad inoculation route, which is widely used in Vaccinia virus 
(VACV) trials. Bank voles from both lineages (all younger than three months) were inoculated via 
footpad with either CPXV RatPox09 or CPXV FM2292 (Table 2, experiment #4). However, neither 
viral shedding in the nasal swabs nor viral DNA in the organ samples could be detected (data not 
shown); however, CPXV-specific antibodies were detected in almost all inoculated animals with 
titers reaching 1:320 for single animals in each group (Table S4), irrespective of the lineage origin of 
the individual (data not shown). In addition, one contact animal, housed together with CPXV 
FM2292-inoculated voles, seroconverted with a high antibody titer (Table S4). Nevertheless, 
seroreactivity did not differ significantly (ANOVA analysis) between animals inoculated with either 
virus strain after footpad inoculation (Table 6). 
Table 6. Seroconversion rate of bank voles inoculated via the footpad method with either CPXV 
RatPox09 or CPXV FM2292 (28 dpi); details see Table S4. 
Footpad Inoculation Positive Antibody Titers # 
CPXV RatPox09 
Inoculated 91.7% 
Contact animals 0% 
CPXV FM2292 
Inoculated 91.7% 
Contact animals 16.7% 
# Antibody titers of ≥1:40 were considered positive. 
  
*
† t-hoc-test between serological reactivity a different lutions (Table S2) groups for p < 0.05; # Antibody titers of
≥40 were considered positive.
3.3. The Evolutionary Bank Vole Lineage Had no Influence on the Results of Intranasal Inoculation with
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I r r t evaluate potential influences of the evolutionary lineage, young voles at an age of four
weeks from the Western and Carpathi n lineage were inoculated intr nasally with CPXV RatPox09
(Table 2, experiment #3). No e of the animals xcreted virus over a period of 14 dpi as proven by
negative swab samples (dat not shown). There was also no vir l DNA detected in the organ samples
(data not shown), and the voles produced only l w amou ts of antibodies with a titer of up to 1:80
(Table S3) that did not differ sig ificantly between the two vole lineages. In addition, one of the
c tact animals showed any signs of infection or seroc version. I teresti gly, with the restriction
that the results were generated in two indepe dent experiments (experi ent #2 and experiment #3),
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younger bank voles exhibited significant (ANOVA analysis, p value of 0.00029) lower seroconversion
rates compared to adult bank voles (greater than four weeks of age).
3.4. Footpad Inoculation Induced No Clinical Signs, but a Strong Antibody Response, Independent of CPXV
Strain and Bank Vole Evolutionary Lineage (Experiment #4)
Next, we investigated the footpad inoculation route, which is widely used in Vaccinia virus
(VACV) trials. Bank voles from both lineages (all younger than three months) were inoculated via
footpad with either CPXV RatPox09 or CPXV FM2292 (Table 2, experiment #4). However, neither viral
shedding in the nasal swabs nor viral DNA in the organ samples could be detected (data not shown);
however, CPXV-specific antibodies were detected in almost all inoculated animals with titers reaching
1:320 for single animals in each group (Table S4), irrespective of the lineage origin of the individual
(data not shown). In addition, one contact animal, housed together with CPXV FM2292-inoculated
voles, seroconverted with a high antibody titer (Table S4). Nevertheless, seroreactivity did not differ
significantly (ANOVA analysis) between animals inoculated with either virus strain after footpad
inoculation (Table 6).
Table 6. Seroconversion rate of bank voles inoculated via the footpad method with either CPXV
RatPox09 or CPXV FM2292 (28 dpi); details see Table S4.







# Antibody titers of ≥1:40 were considered positive.
3.5. Repeated Inoculations with Different CPXV Strains Resulted in Subclinical Infection with a Strong
Antibody Response (Experiment #5)
Finally, a possible booster effect of repeated inoculations was investigated. Therefore, bank voles
were inoculated intranasally with either CPXV Brighton Red, CPXV FM2292 or CPXV RatPox09.
These strains were selected for this experiment as Brighton Red and FM2292 belong to the same clade
CPXV-like 2 (Table 1), while FM2292 and RatPox09 were both isolated from a rodent origin sample.
At 21 dpi the initial inoculation was followed by a second intranasal application of the same virus
strain (Table 2, experiment #5). Swabs were analyzed over a period of 42 days, but no viral DNA could
be detected (data not shown). Half of the CPXV RatPox09-inoculated voles seroconverted. In contrast,
all animals inoculated with CPXV Brighton Red or CPXV FM2292 developed OPV-specific antibodies
reaching higher levels (Table S5). Statistical evaluation revealed significant differences only between
the groups inoculated with CPXV Brighton Red and CPXV RatPox09 (Table 7).
Table 7. Seroconversion rate of bank voles repeatedly inoculated with the same CPXV strain at 42 dpi.
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3.5. Repeated Inoculations with Different CPXV Strains Resulted in Subclinical Infection with a Strong 
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l  . r r i  r t  f  les re eatedly inoculated ith the same CPXV strain at 42 dpi. 
Intranasal Inoculation with Booster Tukey HSD † Positive Antibody Titers # 
CPXV Brighton Red 
 
100% 
CPXV FM2292 100% 
CPXV RatPox09 50% 
† Post-hoc-test between serological reactivity at different dilutions (Table S5) groups for p <0.05;  
# Antibody titers of ≥40 were considered positive. 
4. Discussion 
It has been reported that wild rodents are the reservoir hosts for CPXV [10,11,28], and we 
recently demonstrated the susceptibility of common voles for CPXV by experimental infection [33]. 
However, bank voles evidently are also affected as shown by serological and molecular surveys in 
Eurasia [16–23,25–27]. In addition, recent PCR investigations indicated CPXV infections in bank 
voles mainly of the Western lineage, but also in a single animal of the Eastern lineage ([21]; Fischer, 
Drewes, Ulrich et al., unpublished data). Nevertheless, in these cases, the genome load was very low 
and CPXV could not be isolated. Still, little is known about the pathogenesis of CPXV infections in 
potential reservoir hosts including the bank vole. We therefore conducted a series of experimental 
infections of bank voles to investigate the susceptibility to CPXV infection in this potential reservoir 
host, and compared the data to those from recent experiments with common voles [33]. 
Bank voles from two different evolutionary origins (Western and Carpathian lineage) were 
infected with various CPXV strains originating from either accidental or natural host species and 
belonging to different genetic clades (Table 1). Different inoculation routes were used ranging from 
intranasal to subcutaneous and footpad applications. The experimental layout was limited by the 
animal numbers available at any one time and, therefore, resulted in several independent 
experiments. In addition, the available animals were outbred, which may also account for variability 
between the individual experiments. However, we contend that general patterns of infections are 
deducible from our experiments and a clear picture emerged concerning the clinical outcome. 
4.1. Bank Voles Are Resistant to CPXV-Induced Clinical Signs 
Of note, not a single bank vole in the experiments conducted here exhibited any clinical 
symptoms, although wild rodents have been reported to exhibit clinical signs [24,33,44]; therefore, 
the asymptomatic course of infection observed here is exceptional. The outcome was independent of 
the CPXV strain used, the age, the sex, the inoculation route and the bank vole lineage. Our 
observations support the results of experimental infection of British vole species performed by 
*
st-hoc-test between serological reactivity at different dilutio s (Table S5) groups for p <0.05; # Antibody titers
of ≥40 were considered positive.
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4. Discussion
It has been reported that wild rodents are the reservoir hosts for CPXV [10,11,28], and we
recently demonstrated the susceptibility of common voles for CPXV by experimental infection [33].
However, bank voles evidently are also affected as shown by serological and molecular surveys in
Eurasia [16–23,25–27]. In addition, recent PCR investigations indicated CPXV infections in bank
voles mainly of the Western lineage, but also in a single animal of the Eastern lineage ([21]; Fischer,
Drewes, Ulrich et al., unpublished data). Nevertheless, in these cases, the genome load was very low
and CPXV could not be isolated. Still, little is known about the pathogenesis of CPXV infections in
potential reservoir hosts including the bank vole. We therefore conducted a series of experimental
infections of bank voles to investigate the susceptibility to CPXV infection in this potential reservoir
host, and compared the data to those from recent experiments with common voles [33].
Bank voles from two different evolutionary origins (Western and Carpathian lineage) were infected
with various CPXV strains originating from either accidental or natural host species and belonging
to different genetic clades (Table 1). Different inoculation routes were used ranging from intranasal
to subcutaneous and footpad applications. The experimental layout was limited by the animal
numbers available at any one time and, therefore, resulted in several independent experiments.
In addition, the available animals were outbred, which may also account for variability between the
individual experiments. However, we contend that general patterns of infections are deducible from
our experiments and a clear picture emerged concerning the clinical outcome.
4.1. Bank Voles Are Resistant to CPXV-Induced Clinical Signs
Of note, not a single bank vole in the experiments conducted here exhibited any clinical
symptoms, although wild rodents have been reported to exhibit clinical signs [24,33,44]; therefore,
the asymptomatic course of infection observed here is exceptional. The outcome was independent
of the CPXV strain used, the age, the sex, the inoculation route and the bank vole lineage.
Our observations support the results of experimental infection of British vole species performed
by Bennett et al., which also resulted in subclinical infection [31]. In conclusion, bank voles seem to be
one of the most resistant species for CPVX-induced clinical signs.
4.2. CPXV Replication and Shedding Is Very Limited in Bank Voles
Viral shedding was not detected by nasal and buccal swab testing (irrespective of age, sex,
virus strain, inoculation route and host lineage), and transmission as evidenced by seroconversion
occurred in only 2 out of 18 contact animals (sum of contact animals from all five experiments
performed here). These findings contradict previous studies with a different vole species in which
we showed that experimentally infected common voles (Microtus arvalis) were clinically affected
and excreted virus between 4 dpi and 14 dpi via respiratory secretions [33]. Sensitivity of the
diagnostic tests were demonstrated in the previous study and therefore did not contribute to low
score genome detection. The possible transmission route between individual bank voles remains
elusive, and respiratory transmission seems unlikely. Shedding via urine and feces was reported
from experimentally infected rats [45], and might be a limited source of infectious virus also for naïve
bank voles in the used experimental setup. It cannot be excluded either that shedding below the
detection limit might be sufficient to infect in-contact animals, albeit irregularly. As CPXV has high
tenacity [46], contaminated materials for example grass or hay, may function as fomites and might be
the epidemiological connection resulting in maintenance of the pathogen in their environment.
It is worth noting that not all inoculated animals seroconverted and only some bank voles had
titers above 1:80. Even sequential inoculation did not result in seroconversion of all individuals,
which indicates that the adaptive immune system of bank voles may not be necessary to control
CPXV infection. This is especially true for individuals inoculated with virus strains originating from
central Europe (e.g., CPXV RatPox09 or CPXV/2007/Vole). However, there were some differences
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detected in bank voles infected with isolates from either Great Britain or Finland (CPXV Brighton
Red or CPXV FIN_MAN_2000) compared to the other viral strains used: positive genome loads in
the lungs (at least for Brighton Red considered as replicating virus) and 100% seroconversion rates
that also were concomitant with higher titers. Strikingly, these virus isolates originate from locations
were bank voles, but not common voles, are present. The CPXV-specific seroconversion, therefore,
suggests that bank voles constitute as a possible reservoir host. Generally, common voles have a large
geographic range extending from Spain across much of Western, Central and Eastern Europe all the
way to the Middle East and central Russia [47]. In contrast, common voles are not found in most
parts of southern Europe, Fennoscandia, Northern Russia, Iceland and the British isles (apart from the
Orkney-islands) [47].
One might speculate from our observation (strains from UK and Finland induce 100%
seroconversion in bank voles, that are endemic in UK and Finland) that CPXV strains might be
better adapted to a certain main reservoir host in a given geographic region. As a possible consequence,
virus strains of Central European origin are mainly adapted to the common vole as reservoir host,
while virus strains in Britain or Fennoscandia are more adapted to bank voles. Consequently, in order
to obtain virus isolates originating from reservoir host species, common voles should be sampled
in Central Europe, while bank voles/field voles and wood mice are species to be sampled in UK
and Fennoscandia, respectively. Seroprevalence and molecular survey data indicate CPXV infections
are also occurring in bank voles in Central Europe (Belgium [19], Hungary [27]; Kinnunen 2011;
our unpuplished data). However, these studies categorized sera as “positive” if titers were 1:20 or
higher and could be the result of inefficient replication without efficient transmission. The low genome
copy numbers in the very few PCR-positive bank voles in those field studies also support this and are
in line with the here reported course of experimental infection. From the comparative data presented
here, a robust “cut-off” value of at least 1:40 for scoring sera as reactive against OPV is suggested and
may change the number of seropositive animals in field studies.
4.3. Bank Voles as CPXV Reservoir Host
From the results of our extensive infection experiments we conclude that, on the basis of the
basic minimal definition of a reservoir host as “being a host that transmits, but is not diseased”,
bank voles could indeed present a reservoir host of CPXV, although with inefficient transmission
to other voles. However, the more precise definition of Haydon et al. [48], defining a reservoir
species as “one or more epidemiologically connected populations or environments in which the
pathogen can be permanently maintained and from which infection is transmitted to the defined
target population”, is more challenging. Following this definition, the role of bank voles as a general
reservoir host for CPXV is questionable since the maintenance of the pathogen in a population is a
prerequisite for a reservoir host species. Our studies indicated only limited transmission to contact
animals, ergo facilitating limited maintenance. In contrast to a one host species–one virus association
as specified, e.g., for hantaviruses [49], CPXV strains might be therefore maintained by multiple species
reservoirs. In our opinion, there is generally no unique reservoir host of CPXV rather than a favorite
vole species taking the part of the reservoir within a given geographic region.
The competence of a certain vole species to act as reservoir is dependent on host factors as was
shown for the cycling of Borrelia ssp. in voles and ticks [50]. Additional factors, including co-infections
with bacteria or parasites and a general immunosuppression, might be additive, which will have to
be tested in future experimental setups. Turner et al. analyzed interactions between microparasite
species in field voles and demonstrated that 79% of CPXV-infected animals were co-infected with
either Bartonella spp., Anaplasma spp. or Babesia spp. [29]. Furthermore, stress and fecundity are also
most likely important key factors playing a role in the kinetics of viral replication in voles. Regarding
seroconversions and some hematological parameters, studies of Beldomenico et al. showed in field
voles that a poor body condition significantly increased the probability of CPXV-infection, especially
for males [30].
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In general, experimental infections of reservoir host species are a prerequisite for the dynamic
modeling of infectious (zoonotic) diseases. Virus tropism obviously differs between natural reservoirs
and accidental host species, and we posit that reservoir studies as conducted here are fundamental.
Future studies will have to focus onto the identification of viral genetic markers involved in the
interaction of the reservoir host species and their “matching” CPXV strains. In addition, bank vole
host factors influencing the level of CPXV replication will have to be analyzed in more detail, and we
propose to particularly evaluate the contribution of co-infection and immunosuppression. Finally,
the factors preventing bank voles from clinical signs after CPXV infection should be studied, including
the role of innate immunity.
Supplementary Materials: Supplementary tables are available online at www.mdpi.com/1999-4915/9/12/391/s1.
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